About this Journal Submit a Manuscript Table of Contents
Cholesterol
Volume 2010 (2010), Article ID 306147, 3 pages
http://dx.doi.org/10.1155/2010/306147
Clinical Study

The Effects of Extended Release Niacin in Combination with Omega 3 Fatty Acid Supplements in the Treatment of Elevated Lipoprotein (a)

Brooke Army Medical Center, MCHE MDC Cardiology Service, 3851 Roger Brooke Drive, Fort Sam Houston, TX 78234-6200, USA

Received 28 September 2009; Revised 18 December 2009; Accepted 22 December 2009

Academic Editor: Gerhard M. Kostner

Copyright © 2010 Alan F. Helmbold et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Objective. To assess the effectiveness of niacin/fish oil combination therapy in reducing Lipoprotein (a) [Lp(a)] levels after twelve weeks of therapy. Background. Lipoprotein (a) accumulates in atherosclerotic lesions and promotes smooth muscle cell growth and is both atherogenic and thrombogenic. A clinical trials of combination therapy for the reduction of Lp(a) has not been previously reported. Methods. The study was an observational study following subjects with an elevated Lp(a) ( > 70 nmol/L) to assess impact of 12 weeks of combination Omega 3FA, niacin, and the Mediterranean diet on Lp(a). Results. Twenty three patients were enrolled with 7 patients lost to follow up and 2 patients stopped due to adverse events. The average Lp(a) reduction in the remaining 14 subjects after 12 weeks of combination therapy was 2 3 % ± 17% [ 𝑃 = . 0 0 3 ] with a significant association of the reduction of Lp(a) with increasing baseline levels of Lp(a) [ R 2 = 0 . 6 3 3 , 𝑃 = . 0 0 1 ]. Conclusions. There was a significant reduction in Lp(a) levels with combination therapy. A more pronounced effect was noted in patients with higher baseline levels of Lp(a).